Lupin Builds On Chinese Ambitions With Yabao Alliance
Partnership Will Initially Focus On Pediatric Formulations, With Potential To Expand
Lupin has built on a recent alliance in China with Foncoo by agreeing a further partnership for the Chinese market, this time with Yabao Pharmaceutical.
You may also be interested in...
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Neuraxpharm, Lupin and ANI have announced changes within their leadership teams, while board members have joined industry associations Medicines for Europe and Australia’s GBMA.
Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.